KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Range Low Price High Price Comment
30 days $12.20 $18.02 Friday, 26th Apr 2024 VRDN stock ended at $12.88. This is 1.42% more than the trading day before Thursday, 25th Apr 2024. During the day the stock fluctuated 5.07% from a day low at $12.43 to a day high of $13.06.
90 days $12.20 $21.42
52 weeks $10.93 $28.98

Historical Viridian Therapeutics, Inc. prices

Date Open High Low Close Volume
Apr 26, 2024 $12.74 $13.06 $12.43 $12.88 523 659
Apr 25, 2024 $12.92 $12.96 $12.20 $12.70 923 717
Apr 24, 2024 $14.38 $14.68 $12.99 $13.03 770 411
Apr 23, 2024 $14.39 $15.01 $14.23 $14.25 524 456
Apr 22, 2024 $14.74 $14.74 $14.00 $14.30 803 734
Apr 19, 2024 $15.09 $15.51 $14.40 $14.60 1 465 231
Apr 18, 2024 $15.07 $15.75 $14.93 $15.16 567 166
Apr 17, 2024 $15.20 $15.26 $14.85 $15.08 637 242
Apr 16, 2024 $15.49 $15.54 $15.03 $15.09 666 969
Apr 15, 2024 $15.81 $15.95 $15.20 $15.64 713 385
Apr 12, 2024 $16.27 $16.31 $15.67 $15.89 759 837
Apr 11, 2024 $16.36 $16.47 $15.95 $16.21 549 099
Apr 10, 2024 $16.08 $16.37 $15.53 $16.11 924 811
Apr 09, 2024 $17.02 $17.32 $16.53 $16.85 536 836
Apr 08, 2024 $16.42 $17.10 $16.28 $16.90 520 759
Apr 05, 2024 $16.10 $16.62 $15.71 $16.32 483 296
Apr 04, 2024 $16.41 $16.85 $16.12 $16.32 984 005
Apr 03, 2024 $16.48 $16.80 $16.17 $16.26 544 429
Apr 02, 2024 $16.90 $16.90 $16.42 $16.69 876 649
Apr 01, 2024 $17.69 $17.69 $16.89 $17.26 576 278
Mar 28, 2024 $17.67 $17.86 $17.21 $17.51 940 111
Mar 27, 2024 $17.56 $18.02 $17.14 $17.51 680 588
Mar 26, 2024 $17.86 $17.87 $17.25 $17.37 602 507
Mar 25, 2024 $17.99 $18.33 $17.30 $17.55 744 281
Mar 22, 2024 $18.69 $18.94 $17.85 $18.01 837 850
Click to get the best stock tips daily for free!

About Viridian Therapeutics, Inc.

Viridian Therapeutics. Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as ... VRDN Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT